IDEAYA Enters Into an Additional Clinical Study Collaboration and Supply Agreement with Gilead Sciences
Shots:
- IDEAYA has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences to evaluate the efficacy and safety of IDE397 + Trodelvy in MTAP-Deletion NSCLC
- IDEAYA is currently enrolling patients in a monotx. expansion study for IDE397 in MTAP-deletion NSCLC and urothelial cancer, alongside the P-I/II study evaluating IDE397 with Trodelvy in UC and NSCLC. The company also expects to launch a wholly-owned clinical combination study of IDE397 and IDE892, in the 2H’25
- IDE397 is a selective methionine adenosyl transferase 2a (MAT2A) inhibitor for patients with solid tumours with MTAP deletion
Ref: Prnewswire | Image: IDEAYA & Gilead Sciences
Related News:- IDEAYA Biosciences Partners with Hengrui Pharma to Develop SHR-4849 for Treating SCLC and NET Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
